Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?

Francesco Paneni^{1

2

3}, Sebastiano Sciarretta^{4

5}, Sarah Costantino¹

Affiliations

¹ Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, Schlieren, CH-8952, Switzerland.
² University Heart Center, Cardiology, University Hospital Zurich, Switzerland.
³ Department of Research and Education, University Hospital Zurich, Switzerland.
⁴ Department of AngioCardioNeurology, IRCCS Neuromed, Pozzili, Italy.
⁵ Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.

Editorial

Francesco Paneni et al. Cardiovasc Res. 2021.

. 2021 Jan 21;117(2):343-345.

doi: 10.1093/cvr/cvaa196.

Francesco Paneni^{1

2

3}, Sebastiano Sciarretta^{4

5}, Sarah Costantino¹

¹ Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, Schlieren, CH-8952, Switzerland.
² University Heart Center, Cardiology, University Hospital Zurich, Switzerland.
³ Department of Research and Education, University Hospital Zurich, Switzerland.
⁴ Department of AngioCardioNeurology, IRCCS Neuromed, Pozzili, Italy.
⁵ Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.

No abstract available

Comment on

Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
Kolijn D, Pabel S, Tian Y, Lódi M, Herwig M, Carrizzo A, Zhazykbayeva S, Kovács Á, Fülöp GÁ, Falcão-Pires I, Reusch PH, Linthout SV, Papp Z, van Heerebeek L, Vecchione C, Maier LS, Ciccarelli M, Tschöpe C, Mügge A, Bagi Z, Sossalla S, Hamdani N. Kolijn D, et al. Cardiovasc Res. 2021 Jan 21;117(2):495-507. doi: 10.1093/cvr/cvaa123. Cardiovasc Res. 2021. PMID: 32396609